Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCOV Booster in Adults
NCT05323435Phase 2Completed
- Sponsor
- Recbio
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ReCOV in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Recbio. Primary endpoints: Immunogenicity at Phase II Study at 14 days and Safety at Phase II Study at 6 months. Started May 2022; status: completed.
02
Drugs
ReCOV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05323435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323435.